Vitruvian Partners LLP Takes Position in MaxCyte, Inc. $MXCT

Key Points

• Vitruvian Partners LLP acquired 5,043,356 MaxCyte shares during the second quarter, representing a 4.71% stake and 3.1% of the firm’s holdings. Institutional investors and hedge funds collectively own 68.81% of MXCT.
• Analyst sentiment remains mixed, with one Buy and one Sell rating; MarketBeat lists a consensus rating of Hold and an average price target of $5.00.
• MaxCyte shares opened at $1.27, while the company reported a quarterly loss of $0.08 per share—slightly better than estimates—and revenue of $6.50 million, essentially matching expectations. The company remains unprofitable, with a negative net margin of 114.77%.

Vitruvian Partners LLP bought a new stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 5,043,356 shares of the company's stock, valued at approximately $6,203,328,000. MaxCyte accounts for 3.1% of Vitruvian Partners LLP's holdings, making the stock its 6th biggest position. Vitruvian Partners LLP owned 4.71% of MaxCyte as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MXCT. Capricorn Fund Managers Ltd purchased a new position in MaxCyte in the 1st quarter worth approximately $5,760,000. BlackRock Inc. acquired a new stake in MaxCyte in the second quarter valued at approximately $3,765,000. Brooklands Fund Management Ltd purchased a new stake in shares of MaxCyte during the first quarter valued at approximately $1,538,000. Kennedy Capital Management LLC acquired a new position in shares of MaxCyte during the third quarter worth $3,330,000. Finally, AXA S.A. boosted its stake in shares of MaxCyte by 123.2% in the second quarter. AXA S.A. now owns 2,202,378 shares of the company's stock valued at $4,801,000 after purchasing an additional 1,215,481 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MXCT has been the topic of several analyst reports. Weiss Ratings downgraded shares of MaxCyte from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded MaxCyte from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, MaxCyte currently has a consensus rating of "Hold" and an average target price of $5.00.

MaxCyte Stock Down 3.8%

Shares of MXCT opened at $1.27 on Wednesday. The firm has a market cap of $136.04 million, a price-to-earnings ratio of -3.85 and a beta of 1.48. The business's 50 day moving average is $1.20 and its two-hundred day moving average is $0.98. MaxCyte, Inc. has a 52-week low of $0.64 and a 52-week high of $1.86.

MaxCyte (NASDAQ:MXCT - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The business had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.51 million. MaxCyte had a negative net margin of 114.77% and a negative return on equity of 18.92%. On average, equities analysts expect that MaxCyte, Inc. will post -0.25 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source